<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647111</url>
  </required_header>
  <id_info>
    <org_study_id>RECURE</org_study_id>
    <nct_id>NCT03647111</nct_id>
  </id_info>
  <brief_title>Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer</brief_title>
  <official_title>A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ALK Rearranged Advanced Non Squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the efficacy and safety of Crizotinib as a first-line therapy for
      advanced non-squamous non-small cell lung cancer with ALK-positive mutations in the real
      world.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the study of P11014 and P1029, Crizotinib is a first-line therapy for advanced
      non squamous non small cell lung cancer with positive ALK rearrangement.This study aims to
      explore the efficacy and safety of clozotinib as a first-line therapy for advanced
      non-squamous non-small cell lung cancer with ALK-positive mutations in the real world. Among
      them, ALK positive was based on NGS test results, exploring the new drug resistance mechanism
      of ALK under clozotinib treatment mode and consistency between plasma and tissue detection
      driving genes, and finally assessing the role of plasma dynamic detection driving gene
      mutation spectrum in predicting disease progression risk. A retrospective study of 120
      patients with advanced NSCLC using clozotinib ALK positive mutation was conducted to observe
      the efficacy and safety of clozotinib regimen in the real world.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Approximately 1 years</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Approximately 1 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohorts 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Crizotinib 250mg po bid</description>
    <arm_group_label>Cohorts 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue sample and plasma DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        the patients who diagnosed ALK positive mutation in advanced non squamous non small cell
        lung cancer treated by Crizotinib.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18，Pathologically proven ALK positive mutation in advanced non squamous non small
             cell lung cancer

          -  ALK rearrangement detection method is NGS and Ventana

          -  Primary treatment of first diagnosis

          -  The treatment was Crizotinib 250mg po bid Exclusion Criteria

          -  Patients received antitumor treatment before

          -  Patients with contraindication of chemotherapy

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongchang Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongchang Zhang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>+8613873123436</phone_ext>
    <email>zhangyongchang@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nong Yang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>+8613873123436</phone_ext>
    <email>yangnong0217@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+86 731 89762323</phone>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Nong Yang, MD</last_name>
      <phone>+86 731 89762321</phone>
      <email>yangnong0217@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>ALK rearranged</keyword>
  <keyword>Crizotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

